end-stage renal failure
Conditions
Interventions
960 mg BID of orally L-cysteine is administrated for six-month
2 g BID of orally Lactate as placebo is administrated for six-month
Sponsors
National Defense Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: peritoneal dialysis patients with residual renal function (over 400 ml/day urine volume)
Exclusion criteria
Exclusion criteria: peritoneal dialysis patients without any cancer or acute Inflammation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is the antioxidant effect by oral L-cysteine on peritoneal dialysis patients. Blood reduced glutathione/oxidized glutathione ratio, serum MDA-LDL and plasma homocysteine are measured after six-month oral L-cysteine treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary end point of this study is the preservation of residual renal function and peritoneal function by oral L-cysteine on peritoneal dialysis patients. Beta2-microglobulin and Cystatin C levels are measured after six-month oral L-cysteine treatment as residual renal function. Ay the same time, weekly urea Kt/V and creatinine clearance are assessed as peritoneal dialysis function. | — |
Countries
Japan
Contacts
Public ContactKaori Ishizeki
National Defense Medical College Hospital Department of Blood Purification
Outcome results
None listed